Lupin Ltd LUPIN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP
-
Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP
-
Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
-
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets
-
Lupin Gets FDA Approval for Hyperkalemia Drug
-
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States
-
Lupin to Sell Generic Version of Merck's Bridion in U.S. After FDA Approval
-
Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
Trading Information
- Previous Close Price
- ₹1,935.00
- Day Range
- ₹1,926.50–1,958.40
- 52-Week Range
- ₹1,900.00–2,529.50
- Bid/Ask
- ₹1,953.60 / ₹1,886.60
- Shares Outstanding
- 457.29M
- Market Cap
- ₹893.36B
- Volume/Avg
- 739,314 / 863,589
Key Statistics
- Price/Earnings (Normalized)
- 17.34
- Price/Sales
- 3.00
- Dividend Yield (Trailing)
- 0.93%
- Dividend Yield (Forward)
- 0.93%
- Dividend Payment Schedule
- Aug
- Total Yield
- 0.99%
Company Profile
Lupin Ltd is a transnational pharmaceutical company engaged in producing, developing, and marketing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The Company has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and the Anti-TB and Cephalosporins segments. It operates through two segments: Pharmaceuticals, which consists of producing, developing, and marketing pharmaceutical products, and Others, which consists of diagnostic services, Digital healthcare services, and the neuro-rehabilitation business. The Company operates in India, the USA, and other countries, with maximum revenue from the USA.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 28,137
- Website
- https://www.lupin.com
Valuation
|
Metric
|
LUPIN
|
|---|---|
Price/Earnings (Normalized) | 17.34 |
Price/Book Value | 3.95 |
Price/Sales | 3.00 |
Price/Cash Flow | 14.06 |
Price/Earnings
LUPIN
Financial Strength
|
Metric
|
LUPIN
|
|---|---|
Quick Ratio | 1.27 |
Current Ratio | 1.90 |
Interest Coverage | 17.52 |
Quick Ratio
LUPIN
Profitability
|
Metric
|
LUPIN
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
LUPIN
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|&GtnCZ% | LOCK|F?Ww | $68B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|#yM>pxq | LOCK|<#Hc | $48B | |||
| Haleon PLC ADR
HLN
| LOCK|>$xW$%@ | LOCK|rX | $41B | |||
| Zoetis Inc Class A
ZTS
| LOCK|fmb$<Zc | LOCK|Rf | $31B | |||
| Viatris Inc
VTRS
| LOCK|$<@pr#k | LOCK|&sc | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|&h% | LOCK|l> | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|%<FqM< | LOCK|^!> | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|!m!>?Zn | LOCK|wm | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|&lVwCph | LOCK|q<fF> | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|&GtGG^ | LOCK|$> | $2B |
United States